PRITOR/AMLODIPINE 80 mg/10 mg telmisartan 80 mg/amlodipine (as besilate) 10 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pritor/amlodipine 80 mg/10 mg telmisartan 80 mg/amlodipine (as besilate) 10 mg tablet blister pack

boehringer ingelheim pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: povidone; microcrystalline cellulose; maize starch; pregelatinised maize starch; sodium hydroxide; magnesium stearate; colloidal anhydrous silica; meglumine; sorbitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

PRITOR/AMLODIPINE 80 mg/5 mg telmisartan 80 mg/amlodipine (as besilate) 5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pritor/amlodipine 80 mg/5 mg telmisartan 80 mg/amlodipine (as besilate) 5 mg tablet blister pack

boehringer ingelheim pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; meglumine; magnesium stearate; maize starch; colloidal anhydrous silica; sodium hydroxide; povidone; sorbitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

PRITOR/AMLODIPINE 40 mg/10 mg telmisartan 40 mg/amlodipine (as besilate) 10 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pritor/amlodipine 40 mg/10 mg telmisartan 40 mg/amlodipine (as besilate) 10 mg tablet blister pack

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, multilayer - excipient ingredients: colloidal anhydrous silica; sodium hydroxide; sorbitol; magnesium stearate; pregelatinised maize starch; povidone; microcrystalline cellulose; maize starch; meglumine; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

PRITOR/AMLODIPINE 40 mg/5 mg telmisartan 40 mg/amlodipine (as besilate) 5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pritor/amlodipine 40 mg/5 mg telmisartan 40 mg/amlodipine (as besilate) 5 mg tablet blister pack

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sorbitol; sodium hydroxide; microcrystalline cellulose; povidone; colloidal anhydrous silica; maize starch; pregelatinised maize starch; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Torbugesic 10 mg/ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

torbugesic 10 mg/ml solution for injection

zoetis belgium s.a. - butorphanol tartrate - solution for injection - 10 milligram(s)/millilitre - butorphanol - cats, dogs, horses - neurological preparations

SEDATOR, 1.0 mg/ml, solution for injection for cats and dogs Ireland - English - HPRA (Health Products Regulatory Authority)

sedator, 1.0 mg/ml, solution for injection for cats and dogs

eurovet animal health b.v. - medetomidine hydrochloride - solution for injection - 1.0 milligram(s)/millilitre - medetomidine - cats, dogs - neurological preparations

PRITOR telmisartan 80mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pritor telmisartan 80mg tablet blister pack

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; sorbitol; sodium hydroxide; magnesium stearate; meglumine - pritor is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)